MIDDLE EAST AND ASIA PACIFIC ANTIBODY DRUGS MARKET ANALYSIS

Middle East and Asia Pacific Antibody Drugs Market, by Type (Monoclonal Antibodies, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody), by Disease Indication (Oncology, Neurology, Autoimmune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Middle East (Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, Turkey, Qatar, and Rest of Middle East) and Asia Pacific (South East Asia, The Philippines, Malaysia, Singapore, Thailand, Vietnam, Rest of South East Asia, Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific)) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Mar 2022
Code : CMI4952
Pages :242
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key Players

Major players operating in the Middle East and Asia Pacific antibody drugs market include Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, AbbVie, Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.

Companies covered:

Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, AbbVie, Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.